IE
GHDX

Israel Englander’s Genomic Health, Inc. GHDX Stock Holding History

Israel Englander’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-705,141
Closed -$41M – 4761
2019
Q2 		$41M Buy
705,141
+149,441
+27% +$8.85M 0.06% 423
2019
Q1 		$38.9M Sell
555,700
-62,487
-10% -$4.63M 0.06% 438
2018
Q4 		$39.8M Sell
618,187
-305,777
-33% -$21.4M 0.06% 420
2018
Q3 		$64.9M Sell
923,964
-522,286
-36% -$30.6M 0.08% 319
2018
Q2 		$72.9M Buy
1,446,250
+802,513
+125% +$31.8M 0.1% 263
2018
Q1 		$20.1M Sell
643,737
-55,186
-8% -$1.83M 0.03% 873
2017
Q4 		$23.9M Sell
698,923
-47,080
-6% -$1.5M 0.03% 791
2017
Q3 		$23.9M Buy
746,003
+422,438
+131% +$13.3M 0.04% 688
2017
Q2 		$10.5M Sell
323,565
-146,788
-31% -$4.65M 0.02% 1034
2017
Q1 		$14.8M Sell
470,353
-342,698
-42% -$10.1M 0.03% 815
2016
Q4 		$23.9M Buy
813,051
+83,116
+11% +$2.53M 0.05% 530
2016
Q3 		$21.1M Sell
729,935
-106,350
-13% -$2.96M 0.04% 553
2016
Q2 		$21.7M Sell
836,285
-338,870
-29% -$9M 0.05% 492
2016
Q1 		$29.1M Sell
1,175,155
-130,849
-10% -$3.59M 0.07% 332
2015
Q4 		$46M Buy
1,306,004
+312,476
+31% +$8.37M 0.1% 265
2015
Q3 		$21M Buy
993,528
+553,649
+126% +$14.3M 0.04% 549
2015
Q2 		$12.2M Buy
439,879
+154,522
+54% +$4.36M 0.02% 858
2015
Q1 		$8.72M Sell
285,357
-301,836
-51% -$9.6M 0.02% 1095
2014
Q4 		$18.8M Buy
587,193
+134,753
+30% +$4.39M 0.04% 637
2014
Q3 		$12.8M Buy
452,440
+100,692
+29% +$2.81M 0.03% 733
2014
Q2 		$9.64M Sell
351,748
-18,227
-5% -$485K 0.03% 841
2014
Q1 		$9.74M Buy
369,975
+96,822
+35% +$2.78M 0.03% 823
2013
Q4 		$8M Buy
273,153
+77,879
+40% +$2.47M 0.03% 850
2013
Q3 		$5.97M Buy
195,274
+28,439
+17% +$951K 0.02% 1009
2013
Q2 		$5.29M Buy
+166,835
New +$5.48M 0.02% 989

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Israel Englander's GHDX Position: Q3 2019 in Review

Israel Englander sold out of Genomic Health, Inc. (GHDX) in Q3 2019, closing a stake of 705,141 shares — an estimated $41M sold.

Israel Englander first reported a position in GHDX in Q2 2013 and held it in 25 quarters. The position peaked at $72.9M in Q2 2018. 221 funds tracked by Wall St. Rank hold GHDX as of Q3 2019.

  • Israel Englander reported no remaining Genomic Health, Inc. position as of Q3 2019 after selling out during the quarter.
  • Israel Englander sold 705,141 Genomic Health, Inc. shares in Q3 2019, an estimated $41M.
  • Israel Englander first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 25 quarters.
  • Israel Englander's Genomic Health, Inc. position peaked at $72.9M in Q2 2018.
  • 221 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2019.

Based on Millennium Management's 13F filing for Q3 2019, filed 14 Nov 2019.